Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation
Purpose: EGFR amplification and mutation (i.e., EGFRvIII) are found in 40% of primary GBM tumors and are believed to contribute to tumor development and therapeutic resistance. This study was designed to investigate how EGFR mutational status modulates response to multimodality treatment with cetu...
Main Authors: | Phyllis Rachelle Wachsberger, Richard Yaacov Lawrence, Yi eLiu, Barbara eRice, Constantine eDaskalakis, Adam P Dicker |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00013/full |
Similar Items
-
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase <i>CA2</i> Gene as Resistance Factor
by: Ricarda Hannen, et al.
Published: (2019-06-01) -
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
by: Sabrina Heynckes, et al.
Published: (2019-02-01) -
The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial
by: Cheng, Y., et al.
Published: (2022) -
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
by: Bryan G. Harder, et al.
Published: (2019-11-01) -
RAD-ical New Insights into RAD51 Regulation
by: Meghan R. Sullivan, et al.
Published: (2018-12-01)